Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats

Neuroscience

Volumn 112, Issue 2, 2002, Pages 261-266

  Lu, J Q ^a   Stoessl, A J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Apomorphine; Behavior; Dopamine receptors; Parkinson's disease; Rat

Indexed keywords

APOMORPHINE; CYCLOSOMATOSTATIN; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; OXIDOPAMINE; SOMATOSTATIN; SOMATOSTATIN ANTAGONIST; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; MALE; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ROTATION;

ANIMALS; APOMORPHINE; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; MALE; MEDIAL FOREBRAIN BUNDLE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; SOMATOSTATIN;

EID: 0037129940     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(02)00081-7     Document Type: Article

References (47)

1. Alterations of somatostatin and its modulation by levodopa in MPTP-treated mouse brain
2. 2 receptor antagonists decrease prosomatostatin mRNA expression in rat striatum
3. Evaluation of simple and complex sensorimotor behaviours in rats with a partial lesion of the dopaminergic nigrostriatal system
4. CSF somatostatin-like immunoreactivity in dementia
5. Effects of lesions on somatostatin-like immunoreactitvity in the rat stratum
6. Somatostatin in Alzheimer's disease and depression
7. The regional distribution of somatostatin in the rat brain
8. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications
9. Somatostatin regulates dopamine release in rat striatal slices and cat caudate nuclei
10. Protein kinase C mediates the stimulation by somatostatin of dopamine synthesis in the rat striatum and nucleus accumbens
11. 'Barrel rotation' induced by somatostatin in the non-lesioned rat
12. Low cerebrospinal fluid somatostatin in Parkinson disease: An irreversible abnormality
13. Somatostatin concentrations and binding sites in human frontal cortex are differentially affected in Parkinson's disease associated dementia and in progressive supranuclear palsy
14. CSF somatostatin increase in patients with early parkinsonian syndrome
15. Selective increase in somatostatin mRNA expression in human basal ganglia in Parkinson's disease
16. Cysteamine blocks amphetamine-induced deficits in sensorimotor gating
17. Effects of intracerebroventricularly administered somatostatin on brain monoamine turnover
18. Somatostatin potently stimulates in vivo striatal dopamine and gamma-aminobutyric acid release by a glutamate-dependent action
19. Evidence that somatostatin sst2 receptors mediate striatal dopamine release
20. Somatostatin and thyrotropin releasing hormones: Central effects on sleep and motor system
21. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats
22. Barrel rotation evoked by intracerebroventricular injection of somatostatin and arginine-vasopressin is accompanied by the induction of c-fos gene expression in the granular cells of rat cerebellum
23. Uneven patterns of dopamine loss in the striatum of patients with idiopathic Parkinson's disease
24. Neurobehavioral effects of intrathecal somatostatinergic treatment in subhuman primates
25. Intra-cerebral cysteamine infusions attenuate the motor response to dopaminergic agonists
26. The effects of cysteamine on dopamine-mediated behaviors: Evidence for dopamine-somatostatin interactions in the striatum
27. Regional distribution of neuropeptide somatostatin gene expression in the human brain
28. Effects of somatostatin on dopamine sensitive adenylate cyclase activity in the caudate-putamen of the rat
29. Sulfhydryl drugs reduce neurotoxicity of 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse
30. Motor fluctuations in levodopa treated parkinsonian rats: Relation to lesion extent and treatment duration
31. Somatostatin and its receptor family
32. Turning behaviour in animals
33. Neostriatal administration of somatostatin: Differential effect of small and large doses on behavior and motor control
34. Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity
35. Dopamine enhances somatostatin receptor-mediated inhibition of adenylate cyclase in rat striatum and hippocampus
36. Somatostatin-immunoreactive neurons in the rat striatum: Effects of corticostriatal and nigrostriatal dopaminergic lesions
37. Differential effects of chronic treatment with haloperidol and clozapine on the level of preprosomatostatin mRNA in the striatum, nucleus accumbens, and frontal cortex of the rat
38. Neuroprotective effects of (±)-kavain in the MPTP mouse model of Parkinson's disease
39. Differential regulation of striatal neuropeptide Y and somatostatin containing neurons in the rat
40. Lesions of the dopaminergic nigrostriatal pathway alter preprosomatostatin messenger RNA levels in the striatum, the entopeduncular nucleus and the lateral hypothalamus of the rat
41. Peptide-dopamine interactions in the central nervous system: Implications for neuropsychiatric disorders
42. The effect of amphetamine on the in vivo release of dopamine, somatostatin, and neuropeptide Y from rat caudate nucleus
43. Dopamine-somatostatin interactions in the rat striatum: An in vivo microdialysis study
44. 1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia
45. Comparative sttudies of somatostatin-14 and some of its fragments on passive avoidance behavior, open field activity and on barrel rotation phenomenon in rats
46. Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia